1. Home
  2. RYTM vs CGNX Comparison

RYTM vs CGNX Comparison

Compare RYTM & CGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RYTM
  • CGNX
  • Stock Information
  • Founded
  • RYTM 2008
  • CGNX 1981
  • Country
  • RYTM United States
  • CGNX United States
  • Employees
  • RYTM N/A
  • CGNX N/A
  • Industry
  • RYTM Biotechnology: Pharmaceutical Preparations
  • CGNX Industrial Machinery/Components
  • Sector
  • RYTM Health Care
  • CGNX Industrials
  • Exchange
  • RYTM Nasdaq
  • CGNX Nasdaq
  • Market Cap
  • RYTM 5.9B
  • CGNX 5.7B
  • IPO Year
  • RYTM 2017
  • CGNX 1989
  • Fundamental
  • Price
  • RYTM $88.64
  • CGNX $34.72
  • Analyst Decision
  • RYTM Strong Buy
  • CGNX Buy
  • Analyst Count
  • RYTM 13
  • CGNX 10
  • Target Price
  • RYTM $89.77
  • CGNX $41.30
  • AVG Volume (30 Days)
  • RYTM 1.0M
  • CGNX 1.7M
  • Earning Date
  • RYTM 08-05-2025
  • CGNX 07-30-2025
  • Dividend Yield
  • RYTM N/A
  • CGNX 0.93%
  • EPS Growth
  • RYTM N/A
  • CGNX 20.86
  • EPS
  • RYTM N/A
  • CGNX 0.69
  • Revenue
  • RYTM $136,863,000.00
  • CGNX $919,754,000.00
  • Revenue This Year
  • RYTM $37.47
  • CGNX $6.63
  • Revenue Next Year
  • RYTM $71.16
  • CGNX $10.24
  • P/E Ratio
  • RYTM N/A
  • CGNX $49.70
  • Revenue Growth
  • RYTM 48.88
  • CGNX 8.56
  • 52 Week Low
  • RYTM $40.61
  • CGNX $22.67
  • 52 Week High
  • RYTM $94.80
  • CGNX $51.43
  • Technical
  • Relative Strength Index (RSI)
  • RYTM 71.18
  • CGNX 63.65
  • Support Level
  • RYTM $87.86
  • CGNX $32.55
  • Resistance Level
  • RYTM $92.14
  • CGNX $34.40
  • Average True Range (ATR)
  • RYTM 3.57
  • CGNX 0.92
  • MACD
  • RYTM 1.01
  • CGNX 0.03
  • Stochastic Oscillator
  • RYTM 77.38
  • CGNX 76.15

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.

About CGNX Cognex Corporation

Cognex Corp provides machine vision products that help automate manufacturing processes. The firm's products include vision software, vision systems, vision sensors, and ID products. Vision software combines vision tools with a customer's cameras and peripheral equipment and can help with several vision tasks, including part location, identification, measurement, and robotic guidance. Vision systems combine a camera, processor, and vision software into a single package. Vision sensors deliver simple, low-cost solutions for common vision applications, such as checking the size of parts. ID products read codes that have been applied to items during the manufacturing process. Cognex generates the maximum proportion of its sales in the United States and Europe.

Share on Social Networks: